Peter Wallach

Peter entered the healthcare space after Brian’s diagnosis, originally focusing on investing in targeted therapeutics that had the potential to be truly disease altering in ALS. With Synapticure, Peter hopes to resolve the lack of early intervention, access to quality care, holistic patient data and clear subgrouping of people living with ALS. These shortcomings of the current system have hindered the success of ALS trials broadly and made it difficult to bring forward drugs that focused on specific subsets of the ALS patient population and could better the lives of all people living with ALS.

Prior to working to help solve ALS, Peter worked in the cleantech industry before becoming a consultant at Bain & Company in their Chicago office. Peter received his MBA from Columbia University and undergraduate degree from The University of Virginia.